Protagonist Therapeutics, Inc. (PTGX) Q4 2017 Earnings Results

Protagonist Therapeutics Misses on EPS, Stock Up 1.16%

Protagonist Therapeutics reported a loss per share of $0.15, which did not meet any consensus expectations as revenue figures were not disclosed. Despite this, the stock rose by 1.16%, likely reflecting investor confidence in the company's ongoing research initiatives and future potential. The lack of guidance may lead to uncertainty among investors moving forward.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$-0.15	N/A	N/A
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Neutral

Management did not express strong optimism or concern during the call. They emphasized the importance of their ongoing research efforts.

Management did not provide specific guidance for future quarters.

The call focused on ongoing projects and research developments.

Protagonist Therapeutics Misses on EPS, Stock Up 1.16%

Key numbers

Management commentary

Protagonist Therapeutics, Inc.

More earnings this week

Protagonist Therapeutics Misses on EPS, Stock Up 1.16%

Key numbers

Management commentary